Table 2.
Patient characteristics of individuals with operable breast cancer or asymptomatic carriers of BRCA2 pathogenic variants.
| Age at genetic testing (y.o.) | Age at diagnosis of breast cancer (y.o.) | Stage at diagnosis | Subtype | Breast surgery (y.o.): right/left | Breast reconstruction: right/left | RRSO (y.o.) | |
|---|---|---|---|---|---|---|---|
| 1 | 34 | 34 | IIIC | ER+/HER2− | CRRM (35)/mastectomy (35) | (−)/(−) | 36 |
| 2 | 41 | 41 | IIB | ER+/HER2− | (−)/mastectomy (41) | (−)/(−) | 42 |
| 3 | 43 | 33 | IIIC | ER+/HER2− | Mastectomy (33)/CRRM (45) | (−)/(+) | 44 |
| 4 | 44 | 37 | IIIB | ER+/HER2− | (−)/breast conserving surgery(37) | (−)/(−) | 44 |
| 44 | 37 | I | ER+/HER2− | Breast-conserving surgery (37)/(−) | (−)/(−) | 44 | |
| 5 | 45 | 45 | I | ER+/HER2− | CRRM (45)/mastectomy (45) | (−)/(−) | 46 |
| 6 | 50 | 50 | I | ER+/HER2− | CRRM (50)/mastectomy (50) | (−)/(−) | 50 |
| 7 | 51 | (−) | (−) | (−) | (−)/(−) | (−)/(−) | (−) |
| 8 | 51 | 44 | I | ER+/HER2− | Breast-conserving surgery (44)/(−) | (−)/(−) | (−) |
| 51 | 51 | 0 | ER+/(−) | CRRM (51)/nipple-sparing mastectomy (51) | (+)/(+) | 51 | |
| 9 | 57 | 57 | IIB | ER+/HER2− | CRRM (57)/mastectomy (57) | (−)/(−) | 58 |
| 10 | 58 | 58 | I | ER+/HER2+ | CRRM (58)/mastectomy (58) | (−)/(−) | 50* |
| 11 | 63 | 63 | IIB | ER−/HER2− | (−)/mastectomy (63) | (−)/(−) | (−) |
| 12 | 75 | 34 | I | ER+/HER2− | Mastectomy (34)/(−) | (−)/(−) | (−) |
| 75 | 67 | I | ER+/HER2+ | (−)/breast-conserving surgery (67) | (−)/(−) | (−) |
Cases 4, 8, and 12, who underwent genetic testing at ages 45, 55, and 75, respectively, were single individuals with a history of metachronous bilateral breast cancer. Case 10 did not undergo RRSO; instead, she had undergone bilateral salpingo-oophorectomy at age 50 *for ovarian cancer.
RRSO, risk-reducing salpingo-oophorectomy; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; CRRM, contralateral risk-reducing mastectomy.